Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | ATP4A | P20648 | 1/20 | 0.45 |
| ▸ | ATP4B | P51164 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035149 | 0.93 | MEN1 (0.56) | MEN1KMT2AATMMAPK1NPC1 | |
| SCHEMBL1464842 | 0.91 | MAPK1 (0.55) | MEN1KMT2AMAPK1CYP1A2CYP3A4 | |
| SCHEMBL30028270 | 0.91 | MEN1 (0.56) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6355596 | 0.91 | MEN1 (0.56) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL31040282 | 0.87 | MEN1 (0.47) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1030549 | 0.87 | PDE4A (0.40) | SLC2A1MAOBMEN1KMT2AMAPK1 | |
| SCHEMBL31040288 | 0.87 | MEN1 (0.47) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL30028244 | 0.87 | MEN1 (0.47) | MEN1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10410523 | 0.86 | APP (0.46) | MAOBMEN1KMT2AMAPK1CYP1A2 | |
| SCHEMBL21964294 | 0.86 | S1PR5 (0.50) | MAOBMEN1KMT2AMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805126-B | Preparation method of 2-nitro-4, 5-dibenzyloxy benzyl cyanide | 浙江荣耀生物科技股份有限公司 | 2024-06-18 | — | — | CN | claimed |
| CN-114805126-A | Preparation method of 2-nitro-4, 5-dibenzyloxy benzyl cyanide | 浙江荣耀生物科技股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| US-5508464-A | NITRATING OF A 4,5-DIBENZYLOXYPHENYLACETONITRILE, FOLLOWED BY DEBENZYLATION, HYDROGENATION AND CYCLIZATION | L'OREAL (FR) | 1996-04-16 | — | — | US | claimed |
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | disclosed |
| CN-118421577-B | Tyrosinase mutant and use thereof | 华南理工大学 | 2024-10-01 | — | — | CN | disclosed |
| CN-118421577-A | Tyrosinase mutant and use thereof | 华南理工大学 | 2024-08-02 | — | — | CN | disclosed |
| CN-114805126-B | Preparation method of 2-nitro-4, 5-dibenzyloxy benzyl cyanide | 浙江荣耀生物科技股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-114805126-B | Preparation method of 2-nitro-4, 5-dibenzyloxy benzyl cyanide | 浙江荣耀生物科技股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-117924143-A | Preparation method of 5, 6-dihydroxyindole | 北京成宇化工有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2024-03-21 | — | — | US | disclosed |
| CN-116444569-A | Triphenylhydroxytyrosol and synthesis method thereof and application of triphenylhydroxytyrosol in preparation of medicines for improving aortic endothelial cell functions | 西安交通大学 | 2023-07-18 | — | — | CN | disclosed |
| EP-2007756-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmceuticals Incorporated (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080261895-A1 | Isolated hydroxy and n-oxide metabolites and derivatives of O-desmethylvenlafaxine and methods of treatment | WYETH | 2008-10-23 | — | — | US | disclosed |
| WO-2008051558-A2 | ISOLATED HYDROXY AND N-OXIDE METABOLITES AND DERIVATIVES OF O-DESMETHYLVENLAFAXINE AND METHODS OF TREATMENT | WYETH (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007117715-A2 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | VERTEX PHARMACEUTICALS INCORPORATED | 2007-10-18 | — | — | US | disclosed |
| US-5536865-A | Process for the preparation of 5,6-dihydroxyindole and intermediate compounds | L'OREAL (FR) | 1996-07-16 | — | — | US | disclosed |
| US-5508464-A | NITRATING OF A 4,5-DIBENZYLOXYPHENYLACETONITRILE, FOLLOWED BY DEBENZYLATION, HYDROGENATION AND CYCLIZATION | L'OREAL (FR) | 1996-04-16 | — | — | US | disclosed |
| US-5498746-A | Process for the preparation of 5,6-dihydroxyindole and intermediate compounds | L'OREAL (FR) | 1996-03-12 | — | — | US | disclosed |
| US-5410067-A | Catalytic hydrogenation; cyclization | L'OREAL (FR) | 1995-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092766-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | SLC2A1 74/4885MAOB 3306/4885MEN1 4687/4885 |
| US-20080261895-A1 | Isolated hydroxy and n-oxide metabolites and derivatives of O-desmethylvenlafaxine and methods of treatment | UGT1A4, SLC6A4, UGT1A3 | SLC2A1 468/4885MAOB 88/4885MEN1 4421/4885 |
| US-20070244159-A1 | including Cystic Fibrosis Transmembrane Conductance Regulator (\"CFTR\"), such as 1-(Benzo[d][1,3]dioxol-5-yl)-N-(2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, used for the treatment of genetic disorders such as cystic fibrosis, emphysema, hemochromatosis and protein C deficiency | CFTR, ABCD3, ABCC2 | SLC2A1 214/4885MAOB 3163/4885MEN1 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.